Most Read Articles
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

Adding fulvestrant to anastrozole upfront extends survival in advanced HR+ breast cancer

Pearl Toh
26 Apr 2019

Adding the selective oestrogen-receptor downregulator fulvestrant to the aromatase inhibitor anastrozole in the first-line setting significantly extends long-term progression-free survival (PFS) and overall survival (OS) compared with anastrozole alone in postmenopausal women with hormone-receptor (HR)-positive metastatic breast cancer, according to the final results of the S0226 trial.  

The study also reveals that the survival benefit with the addition of fulvestrant was particularly compelling in women who had not received adjuvant endocrine therapy previously.

“Metastatic HR–positive breast cancer is considered to be incurable,” stated the researchers, who noted that the median OS was only 41.3 months in a previous study, even with many years of disease control in some patients with a third-generation aromatase inhibitor such as anastrozole.  

Over a median follow-up of 7 years (maximum follow-up of 12 years), median OS was 49.8 months in women treated with the combination therapy of fulvestrant + anastrozole compared with 42.0 months in those who received anastrozole alone (hazard ratio [HR], 0.82; log-rank p=0.03). [N Engl J Med 2019;380:1226-1234]

The difference in survival between the two arms was significant despite the substantial number of patients (45 percent) in the anastrozole alone group who subsequently crossed over to receive fulvestrant after disease progression. Analysis of this crossover patient subgroup showed that survival postprogression was similar to that in the combination therapy group, indicating that sequential therapy with anastrozole and fulvestrant did not negate the long-term survival benefit with the combination therapy.  

The results also showed that the timing of treatment matters, according to lead author Dr Rita Mehta from the University of California, Irvine Medical Center, in Orange, California, US. “Women who are treated with fulvestrant upfront live about 8 months longer … That’s a lot of extra time to do the things you love with the people you love,” she said.

Findings in details

The investigator-initiated, multicentre, open-label trial randomized 694 postmenopausal women (median age 65 years) with HR-positive metastatic breast cancer 1:1 to receive anastrozole with or without fulvestrant as first-line therapy. No previous treatment with chemotherapy, immunotherapy, or hormonal therapy was allowed.

The rationale behind the combination therapy stems from the observation that chronic stimulation of oestrogen receptors by low oestradiol levels was one of the resistance mechanisms to anastrozole. Therefore, adding fulvestrant which selectively downregulates oestrogen receptors would be expected to be more effective than anastrozole alone.

The combination therapy group had significantly longer PFS than the anastrozole alone group over a median follow-up of 7 years (median PFS, 15.0 vs 13.5 months, HR, 0.81; log-rank p=0.007).     

“The PFS benefit of upfront combination therapy resulted in prolonged OS,” said Mehta and co-authors.

When the analysis was stratified by previous exposure to adjuvant tamoxifen, the PFS benefit with combination therapy vs anastrozole alone was particularly notable in women who had no prior treatment with tamoxifen (median, 16.7 vs 12.7 months, HR, 0.73, 95 percent confidence interval [CI], 0.60–0.89), whereas PFS was similar between the two arms among those who had previously received tamoxifen (median, 13.6 vs 13.9 months, HR, 0.93, 95 percent CI, 0.73–1.19).    

Similar findings were also seen for OS, whereby the difference between treatment groups was larger among women without prior tamoxifen exposure (median, 52.2 vs 40.3 months, HR, 0.73, 95 percent CI, 0.58–0.92), but similar in patients who had previous treatment with tamoxifen (median, 48.2 vs 43.5 months, HR, 0.97, 95 percent CI, 0.74–1.27).   

Long-term grade 3 toxic effects occurred at similar rates in the combination therapy and the anastrozole alone groups (15 percent vs 13 percent; p=0.47), with events such as fatigue, pain, mood alterations, hot flushes, and gastrointestinal symptoms occurring at frequencies of 1–4 percent. Toxic effects of grade 4 or 5 included two cases of pulmonary emboli and one case of cerebrovascular ischaemic event in the combination therapy group whereas thrombocytopenia, thrombosis or embolism, arthralgia, and dyspnoea were reported in the anastrozole alone group.       

“[The survival] benefit occurred in the absence of clinically significant between-group differences in the incidence of toxic effects of grade 3 to 5 or the discontinuation of treatment, even with long-term follow-up and despite a longer duration of combination therapy,” the researchers noted.

“These results are very exciting," said Mehta. “This is credible evidence that combination endocrine therapy should be considered an option for first-line treatment of advanced HR-positive breast cancer.”




Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.